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Background: Prevalence of hydatidiform mole is not clearly defined, partly because most studies have reported different 
prevalence rates from different regions. However, there is no previous study that has determined the prevalence and associ- 
ated risk factors of HM among patients with incomplete abortion evacuated at Bugando Medical Centre (BMC) and Sekou 
Toure Regional Hospital (STRH). 
Methods: A total of 180 patients with incomplete abortion were enrolled between February 2013 and April 2013. The prod- ucts 
of conception were collected and analyzed using Haemotoxylin and Eosin staining technique for hydatidiform moles. Results: 
One hundred and eighty patients with incomplete abortion scheduled for uterine evacuation agreed to participate in this study. 
The overall prevalence of HM was 12.8%. Majority of patients (27.5%) with HM were those aged below 20 years. No 
significant association was observed with risk factors such as parity, contraceptive use, previous abortion and blood group. 
Conclusion: The prevalence of HM (12.8%) was high and age between 15-20 years was the only significant associated risk 
factor with the presence of HM among patients with incomplete abortion. Therefore, we recommend submission of evac- 
uated products of conception for histopathological analysis to minimize missed opportunity. 
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Hydatidiform mole (HM) is a spectrum of  abnormal 
gestations arising from villous trophoblast associated 
with pregnancy1. HM has two histological types, in- 
cluding partial hydatidiform mole (PHM) and complete 
hydatidiform mole (CHM)2. HM is among gestational 
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ocarcinoma and placenta site trophoblastic tumors that 
arise from villous trophoblast and interstitial tropho- 
blast respectively1. 
 
The prevalence of  HM varies widely in different re- 
gions of the world. Studies conducted in the developed 
countries (North America, Australia, New Zealand and 
Europe) show a prevalence of HM ranging from 0.5- 
1.1 per 1000 pregnancies whereas the higher prevalence is 
seen in Asia and Japan, accounting for 2 per 1000 
pregnancies2. The prevalence of HM in Brazil is 2.2%, 
South Africa 1.2 per 1000 deliveries and Nnewi, South- 
east Nigeria is 0.3 per 1000 deliveries3-6. Considering 
these findings, the prevalence of HM is not universally 
similar and in some countries the prevalence could be 
higher. In Tanzania, the prevalence of HM is not known 
due to the lack of studies investigating this problem. HM 
has several etiological risk factors and the most es- 
tablished are extreme of maternal age and prior molar 
pregnancy7-9. For instance, the risk of  complete mole




increases three fold for women older than forty years 
and is much higher in patients with previous history of 
molar pregnancy10,11. Several studies have shown a sig- 
nificant association between HM and abortion. Acaia et al 
reported that among 93 studied women with repeat- ed 
abortions 9 were found to have HM12. Moreover, 
another study by Horn et al evaluating the histology 
of placenta tissues, reported HM specifically CHM to 
account for 5.1% of the causes of spontaneous abor- 
tion13. 
 
Initial clinical findings are commonly not suggestive of 
the possibility of  HM in patients with abortion. The 
routine  histopathological analysis of  the  evacuated 
products of conception is often not performed in our 
settings. This may lead to the possibility of  misman- 
agement of the patients with HM if this condition is 
missed as the cause of abortion. Therefore, this study 
was designed to determine the prevalence and associat- 
ed risk factors of HM among patients with incomplete 
abortion evacuated at BMC and STRH in Mwanza City, 
North Western Tanzania. 
 
Methods 
This was a cross sectional study design conducted at 
two hospitals namely; Bugando Medical Centre and Se- 
kou Toure Regional Hospital which are situated along 
the shores of Lake Victoria in Mwanza City. The study 
involved patients who were admitted at gynecological 
wards for incomplete abortion between February, 2013 
and April, 2013. The minimum required sample size of 
163 patients with incomplete abortion was obtained by 
using Kish and Lesley formula14. 
 
Data collection 
We collected information on social demographic and 
maternal characteristics using a structured question- 
naire among women who voluntarily consented to par- 
ticipate in the study. The collected products of concep- 
tion from 180 participants after evacuation were stored 
in a container with formalin 10%. The sample collected 
was sent to main laboratory at Bugando Medical centre 




Data entry was done using Microsoft Office Excel 2007 
according to the pre codes and analyzed using the STA- 
TA version 11. Descriptive statistics were obtained for 
socio-demographic and maternal characteristics accord- 
ingly. Categorical variables were summarized into pro- 
portion or percentages, and continuous variables were 
summarized by mean (standard deviation). We assessed 
association between HM and categorical variables using 
chi-square statistical test. Those variables with p-value 
less than or equal to 0.05 were considered at bivariate 
analysis  for logistic regression. Odds ratio was used 
todetermine strength of association and was reported 
with 95% confidence interval. Level of significance for 
this study was 5%, therefore p value of less than 0.05 
was considered statistically significance. 
 
Ethical approval 
The   study  protocol  was  approved  by   CUHAS/ 
BMC ethics review Board with ethical clearance no. 
CREC/016/2013. Participation was voluntary and in- 
formed written consent was sought from each patient 
prior to enrollment. 
 
Results: 
Of  188 patients who consented to participate in this 
study, only 180 patients were eligible and were involved in 
the study. The mean age of  participants was 26.9 
years. Majority of participants (78.3%) were self-refer- ral 
from home and around 42% were housewives. More than 
half of  patients (67.7%) had primary education level 
and around 9% of participants reported being em- 
ployed (Table 1).




Table 1: Social demographic characteristics of the study population 
 














Student 27 15.0 
Employee 16 8.9 
Businesswoman 62 34.4 






Primary 122 67.8 
Secondary 48 26.7 







Married 140 77.8 
Cohabiting 17 9.4 
separated 2 1.1 
 
The overall prevalence of  HM was 12.8% (23/180) 
among patients with incomplete abortion. The prev- 
alence of partial hydatidiform mole (PHM) and com- 
plete hydatidiform mole (CHM) were 11.1% (20/180) 
and 1.7% (3/180), respectively with the rest of the par- 




Figure 1: The prevalence of HM and its pattern




The prevalence of HM was observed to be high (27.5%) 
in the age group between 15-20 years, of which 20% 
had a PHM while 7.5% had a CHM and the association 
was statistically significant (p= 0.01). 
 
Most of the study participants were primiparous 56.1% 
and the prevalence of HM was found to be higher in 
this group (15.8%) compared to the multiparous (9.7%), 
and HM was not  found  among grand multiparous. 
Moreover, thirteen (12.9%) of the primiparous women 
had a PHM while three (3%) had CHM although the 
association between parity and HM was not statistically 
significant (p= 0.29). 
 
Smoking is known to be a risk factor for HM. In this 
study, only 23 patients reported to have history of ciga- 
rette smoking in their lifetime. In this group, the prev- 
alence of HM was 21.7% (5/23) versus 11.5%(18/157) 
higher than those with no history of smoking. Quantity 
and duration of cigarette smoking could not be elicited. 
Eighty five participants (47.2%) had a history of  us- 
ing contraceptives in their lifetime. HM was found in 
12.6% of participants with no history of contraceptive 
use while 12.9% was found in participants with history of 
contraceptive use. Among the participants with no 
history of contraceptive use, nine (9.5%) had a PHM 
and three (3.2%) had a CHM. But no significant associ- 
ation was found between HM and a history of contra- 
ceptive use (p=0.95). 
 
Sixty three (35%) participants had a history of previ- 
ous abortion among whom (14.3%) had HM, while 117 
(65%) had no prior abortion but among them 14 (12%) 
had a HM. Of the 63 participants with previous abor- 
tion 5 (7.9%) had undergone induced abortion and 58 
(92.1%) were spontaneous abortion. Nine (15.5%) of 
participants with spontaneous abortion were diagnosed 
to have HM while none of the participant with induced 
abortion had a HM. However, there was no significant 
association between HM and history of previous abor- 
tion (p=0.66) in this study. None of  the participants 
reported a previous history of HM. 
 
The majority 74 (41.2%) of the participants had blood 
group ‘O’, out of whom 12 (16.2%) had HM. Out of 
35 participants with blood group ‘A’, 7 (20%) had HM 
followed by participants with blood group ‘B’ of whom 
3 (7.5%) had HM. There was no statistically significant 
association which was found between HM and blood 
group (p=0.1) (Table 2).
 
Table 2: Prevalence of HM by maternal characteristics for participants at BMC and 




   Variables                                                         n  (%)                   Normal    tissue (%)           HM (%)                 OR                     95% CI                   p value 
 
Age (years)       
10-19 40 (22.2) 29 (72.5) 11 (27.5) 1 - 0.01 
20-29 78 (43.3) 74 (94.9) 4 (5.1) 0.143 0.04-0.5  
30-39 55 (30.6) 47 (85.5) 8 (14.6) 0.449 0.16-1.3  




Primiparous 101(56.1) 85 (84.2) 16 (15.8) 1 - 0.29 
Multiparous 72 (40) 65 (90.3) 7 (9.7) 0.570 0.2-1.5  
Grandimultiparous 7 (3.9) 7 (100) 0 (0.00) - -  
 
 
Cigarette smoking  
Yes 23 (12.8) 18 (78.3) 5 (21.7) 1 - 0.17 
No 157(87.2) 139 (88.5) 18 (11.5) 0.466 0.15-1.4  
 
Contraceptive use  
Yes 85 (47.2) 74 (87.1) 11 (12.9) 1 - 0.95 













-                   0.66 
•    Induced 5(7.9) 5(100) 0(0.0)   
•    Spontaneous 58(92.1) 49(15.5) 9(15.5)   
No 117(65) 10 3(88.0) 14 (12) 0.816 0.3-2.0 
Previous history of HM      
Yes 0(0.0) 0(0.0) 0(0.0) - -        - 
No 180(100) 157(87.2) 23(12.8) 1 -        - 
Blood group (Rh +ve)       
A 35(19.4) 28(80) 7(20) 1 -0.1-1.4 0 
B 40(22.2) 37(92.5) 3(7.5) 0.32 0.01-1.15 . 
AB 31(17.2) 30(96.8) 1(3.2) 0.13 0.3-2.2 1 
O 74(41.2) 62(83.8) 12(16.2) 1   





The prevalence of HM in this study was found to be 
12.8%, which was similar to the study done in Mexi- 
co15. However, the prevalence of HM in this study was 
higher than previously reported prevalence of HM that 
ranged between 0.3% and 3.4% in other countries. The 
difference could be because most of these studies were 
retrospective and  their sample population involving 
only patients with gestational trophoblastic diseases2-6. In 
Uganda, the prevalence of CHM was found to be 
3.42% which is higher than what we found in our set- 
ting. The prospective study in Uganda involved patients 
with confirmed  CHM clinically and histologically which 
could explain the difference16. 
 
In this study, low extreme of maternal age was strongly 
associated with prevalence of HM (p= 0.01). This was 
consistent with findings observed in other studies9,17,18. 
However, contrarily to other studies which also showed 
the risk to be increased at an age above 40 years, such 
pattern was not observed in this study, possibly because 
in our community, by the age of 40 years, most women 
have completed their family. These contradicting find- 
ings underscore the need for conducting further studies 
involving a larger cohort of patients to establish an ab- 
solute link between HM and the advanced maternal age. 
 
The findings of this study showed that the majority of 
the participants with HM were primiparous (15.8%). 
Moreover, PHM  (12.9%) was more  common  than 
CHM (3%). The risk of  HM was found to decrease 
with an increase in the number of births, but this was 
not statistically significant. Similar result were reported in 
Italy by Parazzini et al but the trend in risk was signif- 
icant only in PHM8. However, the current findings dif- 
fer from those of Kumar et al, who reported the risk of 
HM to increase with parity19. This discrepancy could be 
explained by the fact that the age of majority of multip- 
arous patients in the other studies was above 40 years, 
which is also reported to be a risk for HM. 
 
The results obtained from this study showed 12.9% 
of HM among participants with history of contracep- 
tive use (Table 2). Even though they were few in num- 
ber (47.2%), these findings still concurred with those 
previously reported by a study conducted in USA20. 
Moreover, a large number of participants in this study 
with the diagnosis of HM (12.6%) had no history of 
contraceptive use, which may be a reason for lack of 
association between HM and history of contraceptive 
use (p=0.95). These findings are different from those 
by Palmer et al partly because in their study they used a 
multicenter case control study specifically to establish the 
association of contraceptive use and HM20. 
In this study, 35% participants had history of  previ- 
ous abortion among who (14.3%) had HM, while 65% 
had no prior abortion but among them 12% had HM. 
These findings are similar to those by Parazzini et al 
which showed that the risk of HM increases with histo- 
ry of previous abortion8. Spontaneous type of abortion 
has been found to be more associated with HM than 
induced abortion as was seen in a study done in Italy8. 
This was also reflected in this study in which 15.5% of 
participants with spontaneous abortion were diagnosed 
to have HM while none of the participant with induced 
abortion had HM. 
 
Unlike other studies9,21, in this study there was no par- 
ticipant with previous history of HM. Previous history 
of HM could however not have been ruled out because 
in our settings it is not a standard practice to routinely 
histologically analyze every retained products of con- 
ception  (RPOC) obtained  after  evacuation. Hence, 
there is a possibility that of the 35% of participant with 
previous history of abortion among which 14.3% had 
HM some could have HM in previous abortion. 
In this study, of  all participants with blood group ‘A’ 
20% were found to have HM. This was the highest per- 
centage of  HM as per blood groups. These findings 
are contrary to the study done by Lorigan et al which 
showed blood group ‘B’  to be predominant in cases 
with HM22. However, it is inconclusive to say that par- 
ticipants with blood group ‘A’ are  at an increased risk of 
HM partly because both the study population and other 
risk factors for HM were not evenly distributed based 
on blood group. 
 
Conclusion 
The prevalence of HM was considerably high among 
patient with incomplete abortion attending Bugando 
Hospital and Sekou toure Hospital. Age between 15-20 
years was found to be associated risk factor with di- 
agnosis of HM. Submission of evacuated products of 
conception (POC) for histopathological analysis should 
be considered as the main strategy to know the causa- 
tive factor of abortion. We also recommend analytical 
study to evaluate causal association and predictor of 
malignancy in patients diagnosed with HM. 
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